KR102810262B1 - 중수소화된 jak 저해제를 이용한 탈모 장애의 치료 - Google Patents

중수소화된 jak 저해제를 이용한 탈모 장애의 치료 Download PDF

Info

Publication number
KR102810262B1
KR102810262B1 KR1020237019001A KR20237019001A KR102810262B1 KR 102810262 B1 KR102810262 B1 KR 102810262B1 KR 1020237019001 A KR1020237019001 A KR 1020237019001A KR 20237019001 A KR20237019001 A KR 20237019001A KR 102810262 B1 KR102810262 B1 KR 102810262B1
Authority
KR
South Korea
Prior art keywords
compound
day
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237019001A
Other languages
English (en)
Korean (ko)
Other versions
KR20230086814A (ko
Inventor
아만다 티. 와그너
제임스 브이. 카셀라
필립 비. 그레이엄
버지니아 브라만
비니타 유탐싱
제나 본 헤흔
콜린 이. 해밀턴
Original Assignee
썬 파마슈티칼 인더스트리즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102810262(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 썬 파마슈티칼 인더스트리즈 인코포레이티드 filed Critical 썬 파마슈티칼 인더스트리즈 인코포레이티드
Priority to KR1020257015799A priority Critical patent/KR20250070139A/ko
Publication of KR20230086814A publication Critical patent/KR20230086814A/ko
Application granted granted Critical
Publication of KR102810262B1 publication Critical patent/KR102810262B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237019001A 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료 Active KR102810262B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257015799A KR20250070139A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US62/331,827 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US62/338,869 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US62/418,774 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US62/419,237 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US62/434,404 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US62/466,358 2017-03-02
US201762492758P 2017-05-01 2017-05-01
US62/492,758 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors
KR1020187034867A KR20190003711A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034867A Division KR20190003711A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257015799A Division KR20250070139A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Publications (2)

Publication Number Publication Date
KR20230086814A KR20230086814A (ko) 2023-06-15
KR102810262B1 true KR102810262B1 (ko) 2025-05-19

Family

ID=60203616

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257015799A Pending KR20250070139A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR1020237019001A Active KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR1020187034867A Ceased KR20190003711A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020257015799A Pending KR20250070139A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187034867A Ceased KR20190003711A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Country Status (21)

Country Link
US (3) US10561659B2 (enExample)
EP (2) EP4424367A3 (enExample)
JP (3) JP7145080B2 (enExample)
KR (3) KR20250070139A (enExample)
CN (1) CN109069493A (enExample)
AU (3) AU2017261286B2 (enExample)
BR (1) BR112018072339A2 (enExample)
CA (1) CA3022519A1 (enExample)
DK (1) DK3452039T3 (enExample)
ES (1) ES2988629T3 (enExample)
FI (1) FI3452039T3 (enExample)
HR (1) HRP20241345T1 (enExample)
HU (1) HUE068643T2 (enExample)
LT (1) LT3452039T (enExample)
MX (6) MX388054B (enExample)
PL (1) PL3452039T3 (enExample)
PT (1) PT3452039T (enExample)
RS (1) RS66006B1 (enExample)
SI (1) SI3452039T1 (enExample)
SM (1) SMT202400389T1 (enExample)
WO (1) WO2017192905A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017261286B2 (en) * 2016-05-04 2023-03-23 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
WO2020163653A1 (en) * 2019-02-06 2020-08-13 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) * 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
IL302401A (en) 2020-10-28 2023-06-01 Sun Pharmaceutical Ind Inc Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
EP4384173A1 (en) 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN119255806A (zh) 2022-05-04 2025-01-03 太阳医药工业公司 用于用氘化jak抑制剂进行治疗的剂量方案
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150239896A1 (en) * 2012-06-15 2015-08-27 Concert Pharmaceuticals, Inc. Deuterated Derivatives of Ruxolitinib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP2635299B1 (en) 2010-11-02 2019-07-31 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
KR102135601B1 (ko) 2012-03-29 2020-07-20 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 탈모 질환의 치료 방법
IN2015DN00598A (enExample) * 2012-07-30 2015-06-26 Concert Pharmaceuticals Inc
EP3949953A1 (en) * 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
EA201691582A1 (ru) * 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
AU2017261286B2 (en) 2016-05-04 2023-03-23 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150239896A1 (en) * 2012-06-15 2015-08-27 Concert Pharmaceuticals, Inc. Deuterated Derivatives of Ruxolitinib

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sci. Adv., 2015, 1, e1500973. 2015.*

Also Published As

Publication number Publication date
JP7145080B2 (ja) 2022-09-30
EP3452039B1 (en) 2024-07-03
EP3452039A1 (en) 2019-03-13
JP2022171838A (ja) 2022-11-11
ES2988629T3 (es) 2024-11-21
AU2023201112A1 (en) 2023-03-30
EP4424367A2 (en) 2024-09-04
HRP20241345T1 (hr) 2024-12-20
LT3452039T (lt) 2024-10-25
AU2023201112B2 (en) 2025-05-08
US10561659B2 (en) 2020-02-18
MX2021014175A (es) 2022-01-04
EP4424367A3 (en) 2024-11-13
CA3022519A1 (en) 2017-11-09
MX2018013347A (es) 2019-09-02
AU2017261286B2 (en) 2023-03-23
AU2017261286A1 (en) 2018-11-22
RS66006B1 (sr) 2024-10-31
US20190160068A1 (en) 2019-05-30
BR112018072339A2 (pt) 2019-02-19
US12076323B2 (en) 2024-09-03
HUE068643T2 (hu) 2025-01-28
US20240423986A1 (en) 2024-12-26
JP7586868B2 (ja) 2024-11-19
AU2025213576A1 (en) 2025-08-21
DK3452039T3 (da) 2024-10-07
CN109069493A (zh) 2018-12-21
PT3452039T (pt) 2024-10-07
SMT202400389T1 (it) 2024-11-15
MX2023002323A (es) 2023-03-22
KR20190003711A (ko) 2019-01-09
MX2023002325A (es) 2023-03-22
FI3452039T3 (fi) 2024-10-02
JP2025026895A (ja) 2025-02-26
MX388054B (es) 2025-03-19
KR20250070139A (ko) 2025-05-20
WO2017192905A1 (en) 2017-11-09
PL3452039T3 (pl) 2024-11-18
MX2023002324A (es) 2023-03-22
MX2023002321A (es) 2023-03-22
EP3452039A4 (en) 2019-12-25
US20200222408A1 (en) 2020-07-16
JP2019516684A (ja) 2019-06-20
SI3452039T1 (sl) 2024-12-31
KR20230086814A (ko) 2023-06-15

Similar Documents

Publication Publication Date Title
KR102810262B1 (ko) 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
US10842792B2 (en) Deuterated baricitinib
KR102828163B1 (ko) 중수소화된 cftr 강화제의 투여
US12285432B2 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
US20230390292A1 (en) Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
HK40112813A (en) Treatment of hair loss disorders with deuterated jak inhibitors
HK40002100A (en) Treatment of hair loss disorders with deuterated jak inhibitors
KR20250022668A (ko) 중수소화된 jak 억제제를 이용해 치료하기 위한 투여 요법
OA21444A (en) Regimens For The Treatment Of Hair Loss Disorders With Deuterated Jak Inhibitors.

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230605

Application number text: 1020187034867

Filing date: 20181130

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230801

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20231106

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20250102

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250221

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250514

Application number text: 1020187034867

Filing date: 20181130

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250515

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250515

End annual number: 3

Start annual number: 1

PG1601 Publication of registration